FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3110093044> ?p ?o ?g. }

• W3110093044 endingPage "e2027074" @default.
• W3110093044 startingPage "e2027074" @default.
• W3110093044 abstract "<h3>Importance</h3> The neoadjuvant treatment options for<i>ERBB2</i>-positive (also known as<i>HER2</i>-positive) breast cancer are associated with different rates of pathologic complete response (pCR). The KATHERINE trial showed that adjuvant trastuzumab emtansine (T-DM1) can reduce recurrence in patients with residual disease compared with patients treated with trastuzumab; however, T-DM1 and other<i>ERBB2</i>-targeted agents are costly, and understanding the costs and health consequences of various combinations of neoadjuvant followed by adjuvant treatments in the United States is needed. <h3>Objective</h3> To examine the costs and disease outcomes associated with selection of various neoadjuvant followed by adjuvant treatment strategies for patients with<i>ERBB2</i>-positive breast cancer. <h3>Design, Setting, and Participants</h3> In this economic evaluation, a decision-analytic model was developed to evaluate various neoadjuvant followed by adjuvant treatment strategies for women with<i>ERBB2</i>-positive breast cancer from a health care payer perspective in the United States. The model was informed by the KATHERINE trial, other clinical trials with different regimens from the KATHERINE trial, the Flatiron Health Database, McKesson Corporation data, and other evidence in the published literature. Starting trial median age for KATHERINE patients was 49 years (range, 24-79 years in T-DM1 arm and 23-80 years in trastuzumab arm). The model simulated patients receiving 5 different neoadjuvant followed by adjuvant treatment strategies. Data analyses were performed from March 2019 to August 2020. <h3>Exposure</h3> There were 4 neoadjuvant regimens: (1) HP: trastuzumab (H) plus pertuzumab (P), (2) THP: paclitaxel (T) plus H plus P, (3) DDAC-THP: dose-dense anthracycline/cyclophosphamide (DDAC) plus THP, (4) TCHP: docetaxel (T) plus carboplatin (C) plus HP. All patients with pCR, regardless of neoadjuvant regimen, received adjuvant H. Patients with residual disease received different adjuvant therapies depending on the neoadjuvant regimen according to the 5 following strategies: (1) neoadjuvant DDAC-THP followed by adjuvant H, (2) neoadjuvant DDAC-THP followed by adjuvant T-DM1, (3) neoadjuvant THP followed by adjuvant DDAC plus T-DM1, (4) neoadjuvant HP followed by adjuvant DDAC/THP plus T-DM1, or (5) neoadjuvant TCHP followed by adjuvant T-DM1. <h3>Main Outcomes and Measures</h3> Lifetime costs in 2020 US dollars and quality-adjusted life-years (QALYs) were estimated for each treatment strategy, and incremental cost-effectiveness ratios were estimated. A strategy was classified as dominated if it was associated with fewer QALYs at higher costs than the alternative. <h3>Results</h3> In the base-case analysis, costs ranged from $415 833 (strategy 3) to $518 859 (strategy 4), and QALYs ranged from 9.67 (strategy 1) to 10.73 (strategy 3). Strategy 3 was associated with the highest health benefits (10.73 QALYs) and lowest costs ($415 833) and dominated all other strategies. Probabilistic analysis confirmed that this strategy had the highest probability of cost-effectiveness (>70% at willingness-to-pay thresholds of $0-200,000/QALY) and was associated with the highest net benefit. <h3>Conclusions and Relevance</h3> These results suggest that neoadjuvant THP followed by adjuvant H for patients with pCR or followed by adjuvant DDAC plus T-DM1 for patients with residual disease was associated with the highest health benefits and lowest costs for women with<i>ERBB2</i>-positive breast cancer compared with other treatment strategies considered." @default.
• W3110093044 created "2020-12-07" @default.
• W3110093044 creator A5018607197 @default.
• W3110093044 creator A5023226233 @default.
• W3110093044 creator A5023430660 @default.
• W3110093044 creator A5027148722 @default.
• W3110093044 creator A5056482163 @default.
• W3110093044 creator A5067508184 @default.
• W3110093044 creator A5088826700 @default.
• W3110093044 date "2020-11-23" @default.
• W3110093044 modified "2023-10-10" @default.
• W3110093044 title "Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With<i>ERBB2</i>(<i>HER2</i>)–Positive Breast Cancer" @default.
• W3110093044 cites W2000182266 @default.
• W3110093044 cites W2010030230 @default.
• W3110093044 cites W2014570495 @default.
• W3110093044 cites W2018391204 @default.
• W3110093044 cites W2027571088 @default.
• W3110093044 cites W2045806344 @default.
• W3110093044 cites W2046169609 @default.
• W3110093044 cites W2052592826 @default.
• W3110093044 cites W2055175022 @default.
• W3110093044 cites W2058056848 @default.
• W3110093044 cites W2069324569 @default.
• W3110093044 cites W2075894019 @default.
• W3110093044 cites W2087179076 @default.
• W3110093044 cites W2095861620 @default.
• W3110093044 cites W2103679597 @default.
• W3110093044 cites W2104337757 @default.
• W3110093044 cites W2104554295 @default.
• W3110093044 cites W2123591186 @default.
• W3110093044 cites W2143025931 @default.
• W3110093044 cites W2143405692 @default.
• W3110093044 cites W2148379120 @default.
• W3110093044 cites W2153158488 @default.
• W3110093044 cites W2165371109 @default.
• W3110093044 cites W2169351080 @default.
• W3110093044 cites W2316392947 @default.
• W3110093044 cites W2316887046 @default.
• W3110093044 cites W2519603001 @default.
• W3110093044 cites W2569472942 @default.
• W3110093044 cites W2585697071 @default.
• W3110093044 cites W2618058692 @default.
• W3110093044 cites W2624590002 @default.
• W3110093044 cites W2724318580 @default.
• W3110093044 cites W2731309476 @default.
• W3110093044 cites W2768980003 @default.
• W3110093044 cites W2787103450 @default.
• W3110093044 cites W2788360694 @default.
• W3110093044 cites W2804841700 @default.
• W3110093044 cites W2902218997 @default.
• W3110093044 cites W2905887518 @default.
• W3110093044 cites W2948405934 @default.
• W3110093044 cites W2954662492 @default.
• W3110093044 cites W3011508004 @default.
• W3110093044 cites W4244363181 @default.
• W3110093044 doi "https://doi.org/10.1001/jamanetworkopen.2020.27074" @default.
• W3110093044 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7684449" @default.
• W3110093044 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33226431" @default.
• W3110093044 hasPublicationYear "2020" @default.
• W3110093044 type Work @default.
• W3110093044 sameAs 3110093044 @default.
• W3110093044 citedByCount "8" @default.
• W3110093044 countsByYear W31100930442022 @default.
• W3110093044 countsByYear W31100930442023 @default.
• W3110093044 crossrefType "journal-article" @default.
• W3110093044 hasAuthorship W3110093044A5018607197 @default.
• W3110093044 hasAuthorship W3110093044A5023226233 @default.
• W3110093044 hasAuthorship W3110093044A5023430660 @default.
• W3110093044 hasAuthorship W3110093044A5027148722 @default.
• W3110093044 hasAuthorship W3110093044A5056482163 @default.
• W3110093044 hasAuthorship W3110093044A5067508184 @default.
• W3110093044 hasAuthorship W3110093044A5088826700 @default.
• W3110093044 hasBestOaLocation W31100930441 @default.
• W3110093044 hasConcept C121608353 @default.
• W3110093044 hasConcept C126322002 @default.
• W3110093044 hasConcept C143998085 @default.
• W3110093044 hasConcept C2777863537 @default.
• W3110093044 hasConcept C2777982462 @default.
• W3110093044 hasConcept C2778292576 @default.
• W3110093044 hasConcept C2779786085 @default.
• W3110093044 hasConcept C530470458 @default.
• W3110093044 hasConcept C535046627 @default.
• W3110093044 hasConcept C71924100 @default.
• W3110093044 hasConceptScore W3110093044C121608353 @default.
• W3110093044 hasConceptScore W3110093044C126322002 @default.
• W3110093044 hasConceptScore W3110093044C143998085 @default.
• W3110093044 hasConceptScore W3110093044C2777863537 @default.
• W3110093044 hasConceptScore W3110093044C2777982462 @default.
• W3110093044 hasConceptScore W3110093044C2778292576 @default.
• W3110093044 hasConceptScore W3110093044C2779786085 @default.
• W3110093044 hasConceptScore W3110093044C530470458 @default.
• W3110093044 hasConceptScore W3110093044C535046627 @default.
• W3110093044 hasConceptScore W3110093044C71924100 @default.
• W3110093044 hasIssue "11" @default.
• W3110093044 hasLocation W31100930441 @default.
• W3110093044 hasLocation W31100930442 @default.
• W3110093044 hasOpenAccess W3110093044 @default.
• W3110093044 hasPrimaryLocation W31100930441 @default.

• next